Compare Enveric Biosciences Inc (ENVB) vs Sezzle Inc (SEZL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Sezzle Inc — how do they compare? Enveric Biosciences Inc trades at $1.58 (market cap $6.20M), while Sezzle Inc trades at $124.62 (market cap $4.32B). The key difference: Sezzle Inc is far larger — about 696.8× Enveric Biosciences Inc's market cap, and Sezzle Inc is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ENVB | SEZL | |
|---|---|---|
Market Cap | $6.20M | $4.32B |
Sector | Health | Technology |
52-Week High | $17.40 | $188.55 |
52-Week Low | $1.27 | $50.97 |
Enterprise Value | $1.30M | $4.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.56, up 1.3% on the day, with a bullish technical signal from moving averages and strong analyst support (75% buy ratings). The company reported four consecutive quarterly earnings beats in 2025, including a positive EPS of $0.85 in Q4, while recent news highlights progress in preclinical studies for its non-hallucinogenic psychiatric drug candidate EB-003.
Despite operational losses and negative ROE/ROA, ENVB's consistent earnings surprises and advancing pipeline present speculative growth potential. Key risks include cash burn, clinical trial outcomes, and regulatory hurdles, requiring careful risk assessment by investors.
SEZL stock trades at $125.81, up 6.62% with strong quarterly earnings beats and raised 2026 guidance. The company demonstrates robust fundamentals with 30.35% net income margin and 88.85% ROE, though technical indicators show bearish momentum with current price near support at $125. Recent institutional buying and positive analyst coverage (50% buy ratings) support the growth narrative despite elevated valuation multiples.
The outlook remains positive given consecutive earnings beats and 35% revenue growth guidance, though the stock faces technical headwinds and premium valuation risks. Execution on AI initiatives and everyday money expansion could drive further upside toward the $158.29 consensus target, but investors should monitor margin pressures and competitive threats in the BNPL space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Sezzle Inc
Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →
